Cargando…
Therapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming?
Early humoral immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are dominated by IgM and IgA antibodies, which greatly contribute to virus neutralization at mucosal sites. Given the essential roles of IgM and IgA in the control and elimination of SARS-CoV-2 infection,...
Autores principales: | Zhang, Jingjing, Zhang, Han, Sun, Litao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8890389/ https://www.ncbi.nlm.nih.gov/pubmed/35220888 http://dx.doi.org/10.1080/19420862.2022.2031483 |
Ejemplares similares
-
IgG, IgM and IgA antibodies against the novel polyprotein in active tuberculosis
por: Feng, Xiaoyan, et al.
Publicado: (2014) -
Competition between Serum IgG, IgM, and IgA Anti-Glycan Antibodies
por: Muthana, Saddam M., et al.
Publicado: (2015) -
IgG, IgM, and IgA Antinuclear Antibodies in Discoid and Systemic Lupus Erythematosus Patients
por: Jost, Sheridan A., et al.
Publicado: (2014) -
Role of IgM and IgA Antibodies in the Neutralization of SARS-CoV-2
por: Klingler, Jéromine, et al.
Publicado: (2020) -
Detection of IgE, IgG, IgA and IgM antibodies against raw and processed food antigens
por: Vojdani, Aristo
Publicado: (2009)